Literature DB >> 3596471

Lymph node architecture in Hodgkin's disease: evidence for the role of the composite nodule in nodular sclerosing Hodgkin's disease.

G Van Parys, C De Wolf-Peeters, J J van den Oord, V J Desmet.   

Abstract

The presence or absence of composite nodules, corresponding to recently described structural and functional units in the human reactive lymph node, was investigated in 22 lymph nodes involved by Hodgkin's disease using in situ immuno- and enzymehistochemical techniques. In 10/13 cases of nodular sclerosing subtype, typical composite nodules composed of adjacent B- and T-domains and surrounded by a rim of high endothelial venules were recognized. In association with these venules, a concentrical rim of fusiform shaped Alk Phase+ fibroblastic reticulum cells was observed. Reed-Sternberg cells and their morphological variants were exclusively found in the T-area of these composite nodules. In 5/6 cases of mixed cellularity Hodgkin's disease, B lymphoid follicles were apparent. No vascular relationship with the tumourally involved areas was noticed. In the remaining cases, including all cases of lymphocytic depletion Hodgkin's disease only scattered B cell clusters were recognized. Our observations indicate the persistence of an organoid structure, i.e. the composite nodule in nodular sclerosing Hodgkin's Disease (HD).

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3596471     DOI: 10.1002/hon.2900050209

Source DB:  PubMed          Journal:  Hematol Oncol        ISSN: 0278-0232            Impact factor:   5.271


  2 in total

1.  Morphological and immunohistochemical studies of Hodgkin's disease in the spleen.

Authors:  M Takeshita; S Falk; J Schwetje; H J Stutte
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1989

2.  Diagnostic impact of molecular lineage analysis on paraffin-embedded tissue in hematolymphoid neoplasia reclassified by current WHO criteria.

Authors:  Leonard Hwan Cheong Tan; Lily-Lily Chiu; Evelyn Siew Chuan Koay
Journal:  Mol Diagn Ther       Date:  2007       Impact factor: 4.074

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.